Form 4: Nephros Inc. Director Alisa Lask Reports Stock Option Grant
SEC Form 4 Filing
Director Alisa Lask of Nephros Inc. reported the acquisition of 7,050 stock options on January 1, 2025, as part of her board service compensation.
Summary
- Alisa Lask, a director at Nephros Inc., has reported a transaction involving stock options.
- On January 1, 2025, she acquired 7,050 stock options as part of her compensation for serving on the company's Board of Directors.
- These options vest in three equal installments of 2,350 shares on January 1st of 2025, 2026, and 2027.
- The options have an exercise price of $1.47 and expire on January 1, 2035.
- The report also details other previously granted stock options held by Ms. Lask with various exercise prices and expiration dates.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction of stock options granted to a director, which is generally viewed as neutral to slightly positive as it aligns interests. There are no indications of negative sentiment.
Positives
- The grant of stock options to a director aligns her interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the director.
Risks
- The exercise of these options could potentially dilute existing shareholders' equity if the options are exercised.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for compensating board members across various industries.
- The vesting schedule of the options is typical, encouraging long-term commitment.
- The exercise prices of the options are within the range of what is commonly seen in similar companies.
Stakeholder Impact
- The stock option grant could potentially dilute existing shareholders' equity if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 01/05/2023 | Vesting date for 2,360 shares of a previously granted stock option. |
| 01/05/2024 | Vesting date for 2,360 shares of a previously granted stock option. |
| 05/14/2024 | Vesting date for 2,441 shares of a previously granted stock option. |
| 01/01/2025 | Date of the reported stock option grant of 7,050 shares and vesting date for 2,350 shares of this grant, as well as vesting date for 2,360 shares of a previously granted stock option. |
| 01/01/2026 | Vesting date for 2,350 shares of the reported stock option grant. |
| 05/14/2025 | Vesting date for 2,441 shares of a previously granted stock option. |
| 01/01/2027 | Vesting date for 2,350 shares of the reported stock option grant. |
| 05/14/2026 | Vesting date for 2,441 shares of a previously granted stock option. |
| 02/08/2029 | Expiration date for a previously granted stock option. |
| 12/16/2029 | Expiration date for a previously granted stock option. |
| 01/06/2031 | Expiration date for a previously granted stock option. |
| 12/14/2031 | Expiration date for a previously granted stock option. |
| 01/05/2033 | Expiration date for a previously granted stock option. |
| 05/14/2034 | Expiration date for a previously granted stock option. |
| 01/01/2035 | Expiration date for the reported stock option grant. |
Keywords
stock options, director, insider trading, equity compensation, Nephros Inc., Form 4, Alisa Lask
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.